Abstract:Long‐term intermittent oral administration of a selective cyclooxygenase‐2 inhibitor (COX‐2‐I) for cirrhotic patients significantly decreased the occurrence of severe/critical coronavirus disease 2019 (COVID‐19), acute decompensated events, and acute‐on‐chronic liver failure (ACLF), as well as the symptoms of COVID‐19. The hospitalization and intensive care unit (ICU) admission were therefore reduced. SAR‐S‐CoV‐2, severe acute respiratory syndrome coronavirus 2. Objectives Patients with cirrhosis are more susceptible to coronavirus disease 2019 (COVID‐19) due to immune dysfunction. In this retrospective study we aimed to investigate whether suppression of mild systemic inflammation with selective cyclooxygenase‐2 inhibitor (COX‐2‐I) during chronic care of cirrhotic patients would reduce the occurrence of acute decompensated events and improve patient prognosis of COVID‐19. Methods Medical records of cirrhotic patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection were sequentially reviewed. The patients were divided into the COX‐2‐I and control groups depending on whether they took oral selective COX‐2‐I for over 3 months or not. The primary outcomes included the occurrence of severe/critical COVID‐19, acute decompensated events, and acute‐on‐chronic liver failure (ACLF). Results After propensity score matching analysis, there were 314 cases in the control group and 118 cases in the COX‐2‐I group. Compared with the control group, the risk of severe/critical COVID‐19 in the COX‐2‐I group was significantly decreased by 83.1% (p = 0.004). Acute decompensated events and ACLF occurred in 23 (7.32%) and nine (2.87%) cases in the control group, but none in the COX‐2‐I group (p = 0.003 and 0.122). The rate of hospitalization in the COX‐2‐I group was significantly lower than that of the control group (3.39% vs 13.06%, p = 0.003). No patient in the COX‐2‐I group required intensive care unit admission. Conclusions Long‐term intermittent oral administration of selective COX‐2‐I in cirrhotic patients significantly reduces the occurrence of severe/critical COVID‐19, acute decompensated events, and ACLF. It may also be used for systemic inflammation caused by other pathogens.

Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites

Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites

Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease

Long‐term intermittent oral administration of selective COX‐2 inhibitor improved the clinical outcomes of COVID‐19 in patients with cirrhosis

Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study

Effect of Cyclooxygenase-2 on Liver Fibrogenesis Induced by CCl4 in Rats

Antiangiogenic Effect of a Highly Selective Cyclooxygenase-2 Inhibitor on Gastric Ulcer Healing in Rats

Effects of Cyclooxygenase-2 on Sinusoidal Capillarization in Cirrhotic Rats Induced by Carbon Tetrachloride

Effect of selective COX-2 inhibitor and PGE1 on the expression of VEGF and CTGF in cirrhotic rats

Cyclooxygenase inhibition improves endothelium-dependent vasodilatation in patients with chronic renal failure

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II

Altered renal hemodynamic and excretory function in rats treated with a COX2 inhibitor during the nephrogenic period

Protective Effects of Specific Cyclooxygenase-2 Inhibition in the Treatment of MRL/lpr Mice

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase

Cyclooxygenase-2 Inhibitor (Sc-236) Suppresses Activator Protein-1 Through C-Jun Nh2-Terminal Kinase

Effect of Rofacoxib, a highly selective cyclooxygenase-2 inhibitor, on portal pressure in cirrhotic rats

The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats

Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review

Preservation of vascular endothelial glycocalyx and barrier by activation of adenosine A2A receptor (A2AR) improved renal dysfunction in cirrhotic rats

Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: A systematic review and meta-analysis

Analgesic use and the risk for progression of chronic kidney disease